Pharmaceuticals company AbbVie (ABBV) is in the updates with significant improvements and challenges. The firm has completed the
acquisition of Landos Biopharma, and in another move, it has entered a collaboration with Gilgamesh Pharmaceuticals, aimed at developing the next generation of psychedelic drugs. AbbVie's portfolio has been strengthened with these new deals.
Investors are keeping a keen eye on AbbVie, and Cantor Fitzgerald has initiated coverage of AbbVie with an overweight recommendation. AbbVie also released its first-quarter 2024 financial results, beating both earnings and revenue estimates despite facing revenue challenges. On the downside, the dermatitis sNDA decision for quality medication Rinvoq has been
delayed by the FDA. The company is also notifying of an ongoing slump in Humira sales. Challenges aside, AbbVie maintains a strong reputation as a top value
stock for the long term and an excellent
dividend stock. Moving forward, the Q1 results and other upcoming innovations are anticipated to determine its market trajectory.
Abbvie ABBV News Analytics from Fri, 24 Nov 2023 08:00:00 GMT to Thu, 23 May 2024 20:05:00 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 3
